Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | F2 | P00734 | 5/20 | 0.59 |
| ▸ | F10 | P00742 | 1/20 | 0.59 |
| ▸ | F12 | P00748 | 1/20 | 0.59 |
| ▸ | F7 | P08709 | 1/20 | 0.59 |
| ▸ | F3 | P13726 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PLAU | P00749 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | MASP2 | O00187 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | WDR5 | P61964 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.56 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.56 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.56 |
| ▸ | C1S | P09871 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL394084 | 0.97 | BLM (0.61) | TP53TSHRF2F10F12 | |
| Iodide SCHEMBL7274597 | 0.97 | TP53 (0.60) | TP53TSHRF2F10F12 | |
| SCHEMBL3442777 | 0.93 | WDR5 (0.68) | TP53TSHRF2F10F12 | |
| Hydrochloric Acid SCHEMBL8994023 | 0.91 | PARP15 (0.59) | TP53TSHRF2F10F12 | |
| Benzamidine SCHEMBL10816513 | 0.90 | F2 (0.76) | TP53TSHRF2F10F12 | |
| Terephthalic Acid SCHEMBL7555569 | 0.89 | TSHR (0.71) | TP53TSHRF2PRSS1PRSS3 | |
| Terephthalic Acid SCHEMBL27473772 | 0.83 | TSHR (0.80) | TP53TSHRSRD5A2CA12CA1 | |
| SCHEMBL537030 | 0.83 | LMNA (0.77) | F2F10F12F7F3 | |
| SCHEMBL537029 | 0.81 | LMNA (0.59) | TSHRF2F10F12F7 | |
| Terephthalic Acid SCHEMBL27575972 | 0.80 | TSHR (0.75) | TP53TSHRF2PRSS1PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143634-A | Preparation method of nafamostat mesylate | 北京诺康达医药科技股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| US-11207282-B2 | Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-12-28 | — | — | US | claimed |
| US-20200261386-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-08-20 | — | — | US | claimed |
| EP-0991650-B1 | NOVEL N-BENZENESULPHONYL-L-PROLINE COMPOUNDS, PREPARATION METHOD AND USE IN THERAPY | FOURNIER IND & SANTE (FR) | 2003-09-10 | — | — | EP | claimed |
| US-20030135055-A1 | Aminosulfonylbiphenyl derivatives | MERCK PATENT GMBH (DE) | 2003-07-17 | — | — | US | claimed |
| EP-1286982-A2 | PROCESS FOR THE PREPARATION OF BENZOYL SUBSTITUTED BICYLIC COMPOUNDS AND CHIRAL BNEZOPYRAN DERIVATIVES | Eli Lilly & Company (US) | 2003-03-05 | — | — | EP | claimed |
| EP-0572560-B1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 2003-01-29 | — | — | EP | claimed |
| US-6384222-B1 | BRADYKININ HORMONE ANTAGONIST; ANALGESIC, ANTIINFLAMMATORY; ASTHMA, CEREBRAL TRAUMATIC SHOCK AND ALLERGIC RHINITIS; ETHERIFICATION, AMIDATION | FOURNIER INDUSTRIE ET SANTE (FR) | 2002-05-07 | — | — | US | claimed |
| WO-2001094333-A2 | PROCESS FOR THE PREPARATION OF BENZOYL SUBSTITUTED BICYCLIC COMPOUNDS AND CHIRAL BENZOPYRAN DERIVATIVES | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | claimed |
| EP-0572560-A4 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. | SHAPIRO HOWARD K (US) | 1995-04-26 | — | — | EP | claimed |
| EP-0572560-A1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO, Howard, K. (US) | 1993-12-08 | — | — | EP | claimed |
| WO-1992014456-A1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1992-09-03 | — | — | WO | claimed |
| US-4258030-A | ENZYME INHIBITOR AS STABILIZER | ZERIA-SHINYAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-03-24 | — | — | US | claimed |
| JP-5279315-A | — | — | None | — | — | JP | disclosed |
| EP-4222500-B1 | METHODS OF DETECTING ISOASPARTIC ACID | AMGEN INC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4584387-A1 | MULITIVALENCY FOR ENZYME INHIBITION | Indiana University Research and Technology Corporation (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-0505868-A2 | N-Acyl-alpha-aminoacids derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-09-30 | — | — | EP | disclosed |
| WO-1992014456-A1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1992-09-03 | — | — | WO | disclosed |
| EP-0105201-A2 | Chelate resins, process for their production and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-04-11 | — | — | EP | disclosed |
| US-4258030-A | ENZYME INHIBITOR AS STABILIZER | ZERIA-SHINYAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207282-B2 | Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis | PLAT, PLG, PLAUR | TP53 1381/4885TSHR 895/4885F2 4/4885 |
| US-20030135055-A1 | Aminosulfonylbiphenyl derivatives | APOB, F12, SERPINB1 | TP53 4687/4885TSHR 1770/4885F2 6/4885 |
| US-20200261386-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | TP53 1381/4885TSHR 895/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.